High-Throughput COVID-19 Diagnostic Test that Detects Both Viral and Host Nucleic Acid

Description:
The rapid worldwide spread and impact of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has created a need for accurate, reliable, and readily accessible testing on a massive scale.

NIEHS researchers developed a massively paralleled multiplexed screening method using next generation sequencing (NGS). This method uses sample-specific barcoded indexes that detect both SARS-COV-2 virus and the host’s transcriptional response to infection simultaneously. By matching existing laboratory protocols for PCR-based sample processing, this assay is easily incorporated into existing CLIA-certified facilities. This testing approach provides the capability for testing tens of thousands of patient samples in a large bolus, allowing accurate and fast-turnaround SARS-CoV-2 testing capacity at population scale, and permits monitoring of at-risk individuals.
Patent Information:
For Information, Contact:
Vidita Choudhry
Technology Development Specialist
NIH Technology Transfer
301-594-4095
vidita.choudhry@nih.gov
Inventors:
Brian Papa
Oswaldo Lozoya
Keywords:
Acid
assay
DA4BXX
Diagnosis
HOST
Infection
Massively
Multi-patient
Nucleic
Paralleled
PATHOGENIC
PHYSIOLOGY
sequencing
Surveillance
VLXXXX
WBXXXX
XHXXXX
YAXXXX
YBXXXX
YFXXXX
© 2024. All Rights Reserved. Powered by Inteum